| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Yan Huang, Qing-Hua Zhong, Ying-Yi Kuang, Zhi-Jie Li, Bin-Jie Huang, Yan-Jiong He, Miao-Miao Zhu, Qi Guan, Xiao-Yan Li, Qi-Yuan Qin and Teng-Hui Ma |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Clinical Research 1010 Program of the Sixth Affiliated Hospital of Sun Yat-sen University |
1010CG(2022)-09 |
| Guangdong Provincial Hospital Pharmaceutical Research Foundation |
2021A07 |
| Hospital Pharmaceutical Research Foundation of Guangdong Hospital Association |
YXKY202212 |
| China International Medical Foundation |
Z-2021-46-2101-2023 |
| Program of Guangdong Provincial Clinical Research Center for Digestive Diseases |
2020B1111170004 |
|
| Corresponding Author |
Teng-Hui Ma, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, No. 26 Yuancun Erheng Road, Guangzhou 510655, Guangdong Province, China. matengh@mail.sysu.edu.cn |
| Key Words |
Bleeding; Chronic radiation proctitis; Thalidomide; Efficacy; Safety |
| Core Tip |
Chronic radiation proctitis (CRP) is a common complication of pelvic radiotherapy. Its most frequent symptom is hematochezia, which is often persistent and irreversible. However, the availability of oral drug treatments for hemorrhagic CRP are still extremely limited. This single-arm, open-label, phase II clinical trial investigated the therapeutic efficacy and safety of thalidomide for refractory hemorrhagic CRP. The results demonstrated that thalidomide achieved a hematochezia remission rate of up to 83.9%, with only mild or moderate adverse events. In summary, thalidomide appears to be an effective and well-tolerated treatment option for hemorrhagic CRP. |
| Publish Date |
2026-04-03 06:41 |
| Citation |
Huang XY, Zhong QH, Kuang YY, Li ZJ, Huang BJ, He YJ, Zhu MM, Guan Q, Li XY, Qin QY, Ma TH. Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial. World J Gastroenterol 2026; 32(14): 116529 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i14/116529.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i14.116529 |
